

371042 4276-015
 374277 4276-02
 374904 4277-025
 379137 4279-02
 0074490301 4282-01
 2066-05 4903-34DS



MATERIAL SAFETY DATA SHEET

Product Name: Lidocaine Hydrochloride Injection, USP, 1% & 2%

1. CHEMICAL PRODUCT AND COMPANY INFORMATION

Manufacturer Name And Address: Hospira, Inc.
 275 North Field Drive
 Lake Forest, Illinois 60045
 USA

Emergency Telephone: CHEMTREC: 800-424-9300
 Hospira, Inc.: 224 212-2055

Product Name: Lidocaine Hydrochloride Injection, USP, 1% & 2%

Synonyms: Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-monohydrochloride; 2',6'-Acetoxyilidide, 2-(diethylamino)-, hydrochloride

2. COMPOSITION/INFORMATION ON INGREDIENTS

Active Ingredient Name: Lidocaine Hydrochloride
 Chemical Formula: C₁₄H₂₂N₂O • HCl

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Lidocaine Hydrochloride	≤ 2.0%	73-78-9	AN760000

Non-hazardous ingredients include water and/or sodium chloride. Hazardous ingredients present at less than 1% may include sodium hydroxide and/or hydrochloric acid (used to adjust the pH).

3. HAZARD INFORMATION

Emergency Overview Lidocaine Hydrochloride Injection, USP, 1% or 2%, contains lidocaine hydrochloride, an amide-type local anesthetic used as a local anesthetic for pain management. In the workplace, this product should be considered possibly irritating to the skin, eyes and respiratory tract. Possible target organs include the nervous system and cardiovascular system.

Occupational Exposure Potential Information on the absorption of this product via inhalation or skin contact is not available. Published reports have indicated that similar local anesthetics have some potential to be absorbed through intact skin. Avoid liquid aerosol generation and skin contact.

Signs and Symptoms Inadvertent contact with this product may cause irritation, followed by numbness. Ingestion may cause numbness of the tongue and anesthetic effects on the stomach. In clinical use, this product produces numbness when injected. In normal clinical use, adverse effects may include fever, headaches, agitation, tingling of extremities, general hypotension, bradycardia, dizziness, nausea, vomiting, anemia, back pain, post-operative pain and fetal distress. Systemic absorption can produce central nervous system (CNS) stimulation and/or CNS depression. CNS depression may progress to coma and cardio-respiratory arrest. Signs of cardiovascular toxicity may include changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance. Toxic blood levels may cause atrioventricular block, ventricular arrhythmias, cardiac arrest, and sometimes death. In addition, decreased cardiac output and arterial blood pressure may occur. Allergic-type reactions are rare but may occur due to sensitivity to the local anesthetic or to other formulation ingredients. These reactions are characterized by signs such as urticaria, pruritus, erythema, angioneurotic edema (including laryngeal



3. HAZARD INFORMATION - continued

Signs and Symptoms: continued	edema), tachycardia, sneezing, nausea, vomiting, dizziness, syncope, excessive sweating, elevated temperature, and possibly, anaphylactic-like symptoms (including severe hypotension). Cross sensitivity with other amide-type local anesthetics has been reported.
Medical Conditions Aggravated by Exposure	Pre-existing hypersensitivity to lidocaine or related amide-type anesthetics. Pre-existing nervous system or cardiovascular ailments.
Carcinogen Lists:	IARC: Not listed NTP: Not listed OSHA: Not listed

4. FIRST AID MEASURES

Eye Contact	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Skin Contact	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Inhalation	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Ingestion	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

5. FIRE FIGHTING MEASURES

Flammability	Non-flammable
Fire & Explosion Hazard	None
Extinguishing Media	As with any fire, use extinguishing media appropriate for primary cause of fire.
Special Fire Fighting Procedures	No special provisions required beyond normal fire fighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal	Isolate area around spill. Put on suitable protective clothing and equipment as specified by site spill procedures. Absorb any liquid with suitable material and clean affected area with soap and water. Dispose of spill materials according to the applicable federal, state, or local regulations.
----------------------------	--

7. HANDLING AND STORAGE

Handling	No special handling required under conditions of normal product use.
Storage	No special storage required for hazard control. For product protection, follow USP controlled room temperature storage recommendations noted on the product case label, the primary container label, or the product insert.
Special Precautions	No special precautions are required for hazard controls.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

Component	Exposure Limits		
	OSHA-PEL	ACGIH-TLV	Hospira EEL
Lidocaine Hydrochloride	8 hr TWA: Not Established	8 hr TWA: Not Established	8 hr TWA: 500 mcg/m ³ STEL: 5 mg/m ³

Notes: OSHA PEL: US Occupational Safety and Health Administration - Permissible Exposure Limit
 ACGIH TLV: American Conference of Governmental Industrial Hygienists - Threshold Limit Value.
 EEL: Employee Exposure Limit.
 TWA: 8 hour Time Weighted Average.
 STEL: 15-minute Short Term Exposure Limit.

Respiratory Protection	Respiratory protection is normally not needed during intended product use. However, if the generation of aerosols is likely and engineering controls are not adequate to control potential airborne exposures, the use of an approved air-purifying respirator with a HEPA cartridge (P100) is recommended. Personnel who wear respirators should be fit tested and approved for respirator use as required.
Skin Protection	If skin contact with the product formulation is likely, the use of latex or nitrile gloves is recommended.
Eye Protection	Eye protection is normally not required during intended product use. However, if eye contact is likely to occur, the use of chemical safety goggles (as a minimum) is recommended.
Engineering Controls	Engineering controls are normally not needed during the normal use of this product.

9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical State	Clear, colorless liquid.
Odor	Not determined.
Odor Threshold:	NA
pH:	Between 5.0 and 7.0
Melting point/Freezing point:	Approximately that of water (0 °C, 32 °F).
Initial Boiling Point/Boiling Point Range	Approximately that of water (100 °C, 212 °F).
Evaporation Rate:	NA
Flammability (solid, gas):	NA
Upper/Lower Flammability or Explosive Limits:	NA
Vapor Pressure	Approximately that of water (17.5 mm Hg at 20 °C).
Vapor Density (Air = 1)	NA
Evaporation Rate	NA
Specific Gravity	Approximately that of water (1.0).
Solubility	Very soluble in water and in alcohol; soluble in chloroform; insoluble in ether.
Log Partition coefficient: n-octanol/water:	NA
Auto-ignition temperature	NA
Decomposition temperature	NA



III. STABILITY AND INACTIVITY

Reactivity	Not determined.
Chemical Stability	Stable under standard use and storage conditions.
Hazardous Reactions	Not determined
Conditions to avoid	Not determined
Incompatibilities	Strongly alkaline conditions. Methyl vinyl ether; zinc.
Hazardous Decomposition Products	Not determined. During thermal decomposition, it may be possible to generate irritating vapors and/or toxic fumes of carbon oxides and nitrogen oxides (NO _x), and hydrogen chloride.
Hazardous Polymerization	Not anticipated to occur with this product.

IV. TOXICOLOGICAL INFORMATION

Acute Toxicity:

Not determined for the product formulation. Information for the ingredients is as follows:

Ingredient(s)	Percent	Test Type	Route of Administration	Value	Units	Species
Lidocaine Hydrochloride	100	LD50	Oral	220 292	mg/kg mg/kg	Mouse Mouse
Lidocaine Hydrochloride	100	LD50	Intraperitoneal	122 63	mg/kg mg/kg	Rat Mouse
Lidocaine Hydrochloride	100	LD50	Intravenous	21 15 25.6 24.5	mg/kg mg/kg mg/kg mg/kg	Rat Mouse Rabbit Guinea Pig
Lidocaine Hydrochloride	100	LD50	Intratracheal	28	mg/kg	Rabbit

LD 50: Dosage that produces 50% mortality.

Aspiration Hazard	None anticipated from normal handling of this product.
Dermal Irritation/Corrosion	None anticipated from normal handling of this product. However, inadvertent contact with this product may be irritating to broken skin and mucous membranes, and may produce numbness.
Ocular Irritation/Corrosion	None anticipated from normal handling of this product. However, inadvertent contact of this product with eyes may produce irritation, numbness, and blurred vision.
Dermal or Respiratory Sensitization	None anticipated from normal handling of this product. However, inadvertent contact of this product with the respiratory system may produce irritation and numbness. Rarely, allergic-type reactions have been reported during the clinical use of lidocaine.

11. TOXICOLOGICAL INFORMATION - continued

Reproductive Effects

In a fertility study in rats, lidocaine given subcutaneously at a dosage of 30 mg/kg (180 mg/m²) to mating pairs did not produce alterations in fertility or general reproductive performance of rats. Subcutaneous administration of lidocaine to pregnant rats at a dosage of to 50 mg/kg did not produce evidence of harm to the fetus. In rabbits, there was no evidence of harm to the fetus at a subcutaneous dosage of 5 mg/kg. Treatment of rabbits with a subcutaneous dosage of 25 mg/kg produced evidence of maternal toxicity and evidence of delayed fetal development, including a non-significant decrease in fetal weight and an increase in minor skeletal anomalies. The effect of lidocaine on post-natal development was evaluated in rats by treating pregnant female rats daily subcutaneously at dosages of 2, 10, and 50 mg/kg from day 15 of pregnancy and up to 20 days post partum. No signs of adverse effects were seen either in dams or in the pups up to and including the dose of 10 mg/kg; however, the number of surviving pups was reduced at 50 mg/kg, both at birth and the duration of lactation period; this effect is most likely secondary to maternal toxicity. A second study evaluated the effects of lidocaine on post-natal development in the rat that included assessment of the pups from weaning to sexual maturity. Rats were treated subcutaneously for 8 months with 10 or 30 mg/kg lidocaine, a treatment duration that included 3 mating periods. There was no evidence of altered post-natal development in any offspring; however, both doses of lidocaine significantly reduced the average number of pups per litter surviving until weaning of offspring from the first 2 mating periods.

Mutagenicity

The mutagenic potential of lidocaine was evaluated in the Ames Salmonella reverse mutation assay, an *in vitro* chromosome aberrations assay in human lymphocytes and in an *in vivo* mouse micronucleus assay. There was no indication of any mutagenic effect in these studies.

Carcinogenicity

Long-term studies in animals to evaluate the carcinogenic potential of most local anesthetics, including lidocaine, have not been conducted.

Target Organ Effects

Based on clinical use, possible target organs include the nervous system and the cardiovascular system.

12. ECOLOGICAL INFORMATION

Aquatic Toxicity

Not determined for product.

Persistence/Biodegradability

Not determined for product.

Bioaccumulation

Not determined for product.

Mobility in Soil

Not determined for product.



13. DISPOSAL CONSIDERATIONS

Waste Disposal	If discarded as produced, this product is not a RCRA "listed" or "characteristic" hazardous waste. However, uses resulting in a chemical or physical change of the product or contamination of the product with other materials may subject it to regulation as a hazardous waste. All waste materials must be properly characterized by the waste generator. Further, disposal of all pharmaceuticals should be performed in accordance with the federal, state or local regulatory requirements.
Container Handling and Disposal	Dispose of container and unused contents in accordance with federal, state and local regulations.

14. TRANSPORTATION INFORMATION

DOT STATUS:	Not Regulated
Proper Shipping Name:	NA
Hazard class:	NA
Un number:	NA
Packing group:	NA
Reportable quantity:	NA
ICAO/IATA STATUS	Not regulated
Proper shipping name:	NA
Hazard class:	NA
Un number:	NA
Packing group:	NA
Reportable quantity:	NA
IMDG STATUS	Not regulated
Proper shipping name:	NA
Hazard class:	NA
Un number:	NA
Packing group:	NA
Reportable quantity:	NA

Notes: DOT - US Department of Transportation Regulations

15. REGULATORY INFORMATION

TSCA Status	This product is exempt. However, lidocaine hydrochloride is listed on the TSCA inventory.
CERCLA Status	Not listed
SARA 302 Status	Not listed
SARA 313 Status	Not listed
RCRA Status	Not listed
PROP 65 (Calif.)	Not listed

Notes:

TSCA, Toxic Substance Control Act;
 CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act;
 SARA, Superfund Amendments and Reauthorization Act;
 RCRA, US EPA, Resource Conservation and Recovery Act;
 Prop 65, California Proposition 65

REGULATORY INFORMATION continued

U.S. OSHA Classification Possible Irritant
Target Organ Toxin

GHS Classification

Hazard Class	Acute Oral Toxicity	Eye Irritation	Target Organ Toxicity
Hazard Category	Unclassified	2B	2

Symbol



Signal Word

Warning

Warning

Hazard Statement

Causes eye irritation

May cause damage to the nervous system and cardiovascular system through prolonged or repeated exposure.

Prevention: Do not breathe vapor or spray.

Response: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention. Wash hands after handling.

Get medical attention if you feel unwell.

EU Classifications*

*Medicinal products are exempt from the requirements of the EU Dangerous Preparations Directive. Information provided below is for the pure drug substance lidocaine hydrochloride.

Classification(s):

Harmful

Irritant

Symbol:



Indication of Danger

Xn

Xi

Risk Phrases:

R22 -- Harmful if swallowed

R36/37 - Irritating to eyes and respiratory system

Safety Phrases:

S23: Do not breathe vapor/spray

S24: Avoid contact with the skin

S25: Avoid contact with eyes

S37/39 Wear suitable gloves and eye/face protection.

OTHER INFORMATION

Notes:

ACGIH TLV	American Conference of Governmental Industrial Hygienists -- Threshold Limit Value
CAS	Chemical Abstracts Service Number
CERCLA	US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
DOT	US Department of Transportation Regulations
EEL	Employee Exposure Limit
IATA	International Air Transport Association
LD ₅₀	Dosage producing 50% mortality
NA	Not applicable/Not available
NE	Not established
NIOSH	National Institute for Occupational Safety and Health
OSHA PEL	US Occupational Safety and Health Administration -- Permissible Exposure Limit
Prop 65	California Proposition 65
RCRA	US BPA, Resource Conservation and Recovery Act
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
STEL	15-minute Short Term Exposure Limit
TSCA	Toxic Substance Control Act
TWA	8-hour Time Weighted Average

MSDS Coordinator: Global Occupational Toxicology
Date Prepared: March 5, 2008

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.